Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-09-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mriplannedundergoingcontrastchronic
  Phrases that lowered it: participantsparticipantpatientstumorslesions
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 40.2% (lowers risk) · Drug's FDA history
• Primary purpose: diagnostic (lowers risk) · Design
• Sponsor's past trials: 902 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 70 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 2.1% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 7.2% (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems NCT05915702 · started 2023 · scored riskier than 19% of active trials completed
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) NCT05915728 · started 2023 · scored riskier than 30% of active trials completed
• Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging NCT01660841 · started 2012 · scored riskier than 21% of active trials completed
• Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging NCT00709852 · started 2008 · scored riskier than 38% of active trials completed
• P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) NCT02633501 · started 2016 · scored riskier than 60% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.